Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
44 hedge funds and large institutions have $13.5M invested in Aptose Biosciences, Inc. in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 5 closing their positions.
1% more capital invested
Capital invested by funds: $13.4M → $13.5M (+$98.2K)
6% less funds holding
Funds holding: 47 → 44 (-3)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$241K |
| 2 |
Jane Street
New York
|
+$7.84K |
| 3 |
Morgan Stanley
New York
|
+$4.94K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.61K |
| 5 |
JAWM
J. Arnold Wealth Management
Youngstown,
Ohio
|
+$1.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$693K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$214K |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
-$200K |
| 4 |
Renaissance Technologies
New York
|
-$107K |
| 5 |
Millennium Management
New York
|
-$107K |
APTO Hedge Fund Activity: Q1 2023 in Review
44 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q1 2023, worth a combined $13.5M — up 0.73% from $13.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of APTO and 4 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 5 added.
The largest buyer was Sigma Planning Corp, adding an estimated $241K. The largest seller was Nantahala Capital Management, cutting an estimated $693K.
- 44 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q1 2023, down from 47 in Q4 2022.
- Funds reported $13.5M of Aptose Biosciences, Inc. stock for Q1 2023, up 0.73% quarter-over-quarter.
- 4 funds opened new Aptose Biosciences, Inc. positions in Q1 2023 and 5 closed out, a net change of -1 holder.
- The largest Aptose Biosciences, Inc. buyer in Q1 2023 was Sigma Planning Corp, an estimated $241K added.
- The largest Aptose Biosciences, Inc. seller in Q1 2023 was Nantahala Capital Management, an estimated $693K sold.
Based on aggregated 13F filings for Q1 2023.